A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

In this double-blind Phase II trial (n=320), semaglutide was associated with a higher rate of NASH resolution with no worsening of fibrosis (59% for 0.4mg vs 17% placebo; P<0.001), but there was no significant difference in the proportion with an improvement in fibrosis stage.

New England Journal of Medicine